Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11845MR)

This product GTTS-WQ11845MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11845MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1066MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6356MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ14790MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ10859MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ12879MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ7534MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-182
GTTS-WQ1734MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ3759MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW